Atomoxetine
- Generic Name
- Atomoxetine
- Brand Names
- Strattera
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO
- CAS Number
- 83015-26-3
- Unique Ingredient Identifier
- ASW034S0B8
- Background
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associat...
- Indication
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Associated Therapies
- -
Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 240
- Registration Number
- NCT00191295
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Wakayama, Japan
Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 232
- Registration Number
- NCT00183391
- Locations
- 🇺🇸
University of Illinois, Chicago - Institute for Juvenile Research, Chicago, Illinois, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-07-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 241
- Registration Number
- NCT00174226
- Locations
- 🇺🇸
Pfizer Investigational Site, Woodstock, Vermont, United States
Atomoxetine for the Treatment of Cannabis Dependence
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 16
- Registration Number
- NCT00167297
- Locations
- 🇺🇸
University of Pennsylvania Treatment Rersearch Center, Philadelphia, Pennsylvania, United States
Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 30
- Registration Number
- NCT00161031
- Locations
- 🇺🇸
Veterans Affairs Maryland Health Care System, Baltimore, Maryland, United States
🇺🇸Maryland Psychiatric Research Center, Catonsville, Maryland, United States
Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder
- Conditions
- Interventions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 2
- Registration Number
- NCT00142961
- Locations
- 🇺🇸
Phoenix House, New York, New York, United States
A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
- Conditions
- First Posted Date
- 2004-08-18
- Last Posted Date
- 2006-07-20
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00089869
- Locations
- 🇺🇸
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician., Chula Vista, California, United States
🇺🇸For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Irving, Texas, United States
🇺🇸"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician.", San Antonio, Texas, United States
Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD
- Conditions
- First Posted Date
- 2002-01-17
- Last Posted Date
- 2010-04-28
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 24
- Registration Number
- NCT00029614
- Locations
- 🇺🇸
Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.